Physician profile
Nataly M Bailey
NPI 1386110542
$9,843.89
in general payments reported to CMS, 2019-2025
39 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $469 · 2023: $540 · 2024: $7,482 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,619 · Consulting Fee: $3,460 · Travel and Lodging: $2,216 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,618.60 |
| Consulting Fee | $3,460.00 |
| Travel and Lodging | $2,215.80 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,121.56 | 2024 | Xifaxan, Relistor, Trulance |
| Gilead Sciences, INC. | $2,442.57 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $412.61 | 2023-2025 | Erleada, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $293.95 | 2022-2025 | Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $254.53 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $210.42 | 2022-2025 | Opdivo |
| Glaxosmithkline, LLC. | $188.71 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $179.12 | 2023-2025 | Libtayo |
| Eisai INC. | $142.76 | 2022-2025 | |
| Abbvie INC. | $126.64 | 2022-2025 | |
| Lilly USA, LLC | $118.74 | 2022 | |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Hologic Sales and Service, LLC | $102.71 | 2024-2025 | Aptima |
| Daiichi Sankyo INC. | $98.76 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $91.39 | 2024-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nataly Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.